A Study of ARQ 197 in Combination With Erlotinib

NCT01251796 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced/Recurrent Non-small-cell Lung Cancer

Interventions

DRUG: ARQ 197 and Erlotinib

Sponsor

Kyowa Kirin Co., Ltd.